DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CIML NK Cell in Head & Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
GVAX Plus Checkpoint Blockade in Neuroblastoma
- Status
- TERMINATED
- Phase
- PHASE1
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
- Status
- TERMINATED
- Phase
- PHASE1
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
- Status
- WITHDRAWN
- Phase
- PHASE2